Lyra Therapeutics, Inc. Overview
Pro stress-test →Lyra Therapeutics is a clinical-stage biotech company developing long-acting, anti-inflammatory nasal inserts for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million Americans. The company's lead candidate LYR-210 is a bioabsorbable nasal mesh designed to deliver six months of continuous medication via a simple in-office procedure.
Strategic Profile
Pro stress-test →Lyra demonstrated clinical success with positive Phase 3 ENLIGHTEN 2 data in June 2025, meeting primary endpoints. However, the company announced in January 2026 that its Board suspended further LYR-210 development and ceased operations while pursuing strategic alternatives, representing a significant strategic pivot amid capital constraints.
Competitive Landscape
Pro stress-test →Direct competitors in sinonasal delivery include emerging biotech firms, though CRS treatment remains underserved with limited approved therapies. Broader competition includes conventional systemic and topical anti-inflammatory treatments, saline rinses, and surgical interventions. Lyra's unique drug-delivery mechanism differentiates it but execution risk is elevated.
Industry Context
Lyra Therapeutics, Inc. operates in Biotechnology - Specialty Pharmaceuticals (ENT/Inflammation).
Key facts
Founded: 2005 · Headquarters: Watertown, MA · Employees: 28 · Revenue: $600K · Market cap: $3.5M